Cytokinetics Inc. Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
pleasure to introduce Cytokinetics. We are excited to talk to them today. I want to introduce Isaac Ciechanover, who is the Executive Vice President of Corporate Development and Chief Business Officer, and Dan Jacoby, Vice President of Clinical Research. It is a pleasure to have you both here. My name is Jeffrey Walch. I am one of the analysts at Bernstein. I lead the U.S. biotechnology analysis, and I am excited to have a nice conversation with the Cytokinetics team here and introduce them to our investors at the symposium. Thank you both for joining us. Do you have any prepared remarks that you would like to start with, or I can start off with questions? It is up to you.
Just wanted to, first of all, thank you so much for giving us the opportunity to come and introduce you to our company and answer some questions.
Absolutely. Well, thank you both for being here. I will just ask questions and then let the two of you decide who is going to answer and what the flow is. Maybe you could start just with some context setting. Could you give us an overview of the history of Cytokinetics as a company?
For many of you who follow biotechnology, Cytokinetics is a great example of a company with 25 years of development and an overnight success when the reality of it is the company was started in 1997, went into operations in 1998 in South San Francisco. It was started by a number of academics with insight about cellular mechanics, hence the name Cytokinetics.
and their function in potential in multiple indications. Their original focus for the company was in oncology and antifungal. But some real insights by our early scientists, specifically Fady I. Malik, about the potential of the sarcomere being a target and playing a role in the cardiovascular space, refocused the company and we're really the pioneers of the CMI space.
Yeah. Every major therapeutic that's come in that area or being developed comes out of that seminal work that Fady did.
That's amazing. It's great to hear a science story become true for patients and help patients and that's really wonderful. Maybe moving then beyond just an introduction of Cytokinetics and transitioning over to maybe could you highlight the current scientific and clinical stage focus of the company, and then we can maybe dive into some of the specific programs.
Sure. I can grab that. So right now, Cytokinetics is a commercial company, selling and developing drugs in the cardiovascular space, specifically CMIs. MYQORZO was launched this year in the U.S., and now in Europe, for obstructive HCM, so hypertrophic cardiomyopathy. We have a sales force in the U.S. We're launched in Germany, we'll be expanding in Europe. We have partners in China with Sanofi, Japan with Bayer, and our focus really is in the cardiovascular space. That being said, the history of the company is very strong in the muscle biology, so we don't define ourselves as a cardiac company. We continue to develop new agents for conditions in skeletal muscle as well, and so while in the near term, you should expect us to continue to focus on specialty cardiology.
Our goal is to expand well beyond that, and we will do that through both internal means as well as external.
That is great. Then as you highlight your projection to grow and your sort of future Vision 2030, is there just for our investors that know more mature companies that maybe are a larger cap, is there any sort of archetype for another company that you see best reflecting the Cytokinetics potential trajectory? You can give a timeline for that.
Sure. We do not model ourselves against any company. As I joked, it really was 27 years. I do not know anybody's business plan- Yeah suggested that growth.
Yeah. Our focus is to be the leading specialty cardiology-focused company in the near term.
What that means is to build on the strength of MYQORZO in the obstructive space. We will be talking a little bit about the ACACIA-HCM data, which, if approved, will allow us to be the only therapeutic. In the non-obstructive area we have a rich pipeline, which we will talk about as well.
The growth trajectory for this company is very strong.
We have had some really fantastic growth in the early stages, but we are in the early innings of a launch. There have been many plans in regards to how we want to continue to augment Yeah both making sure that MYQORZO is in the hands of physicians worldwide.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring